Agios Pharmaceuticals (AGIO)

$21.74 0.24 (1.09%)

16:00 EDT AGIO Stock Quote Delayed 30 Minutes

7 Biotech Stocks That Could Be the Next Big Thing

By Josh Enomoto, InvestorPlace Contributor Mar 15, 2023

Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough.

7 Best Biotech Stocks to Buy in 2021 with Huge Upside

5 Biotech Stocks That Could Face M&A Next!

Agios Pharmaceuticals, Inc.Stock Is an Analyst Darling for Good Reason

More Articles

Volume:

Previous Close -

Market Cap 1.28B

PE Ratio -5.13

EPS -4.24

Volume (Avg. Vol.) 603,436

Day's Range $21.07 - $21.94

52-Week Range $16.75 - $34.76

Dividend & Yield N/A (N/A)

AGIO Stock Predictions, Articles, and Agios Pharmaceuticals News

From InvestorPlace
From the Web

7 ‘Strong Buy’ Stocks With 100% Wall Street Support

By Harriet Lefton, Writer, TipRanks Nov 17, 2017

These seven rare stocks have received only "buy" ratings from Wall Street's best analysts, with more upside predicted to come.

Liberty Sirius XM Group (LSXMK) Lead 12 Activist Investor Reports

By Fintel Apr 25, 2017

Recent 13-D and 13-G filings are windows into activist investors activity. We look at Liberty Sirius XM Group and 11 others

40 Biotechnology Stocks to Sell Now

By Portfolio Grader Dec 12, 2016

This week, the overall grades of 40 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

40 Biotechnology Stocks to Sell Now

By Portfolio Grader Dec 5, 2016

The overall ratings of 40 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

Why Agios Pharmaceuticals Inc (AGIO), LPL Financial Holdings Inc (LPLA) and Humana Inc (HUM) Are 3 of Today’s Worst Stocks

By James Brumley, InvestorPlace Feature Writer Dec 5, 2016

Agios (AGIO), LPL Financial (LPLA) and Humana (HUM) were wishing the weekend could have lasted one more day on Monday.

10 Stocks That Should Be in Your Portfolio Right Now

By Johnson Research Group Sep 22, 2016

These 10 stocks to buy are the perfect way to load up before the seasonally strong October-through-December period.

22 Biotechnology Stocks to Sell Now

By Portfolio Grader Jul 11, 2016

This week, 22 Biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

7 Healthcare Stocks That Are Portfolio Poison

By Louis Navellier, Editor, Growth Investor Jan 15, 2016

The market loves to watch a stock grow as much as a parent loves to watch their child grow. Buy, much like toddlers, these healthcare stocks are tumbling.

3 Stocks With Plunging Prices

By James Brumley, InvestorPlace Feature Writer Dec 23, 2014

Here's why Agios Pharmaceuticals Inc (AGIO), Zulily Inc (ZU) and Aruba Networks, Inc. (ARUN) are three of today's worst stocks.

5 Overhyped Stocks to Sell Now

By James Brumley, InvestorPlace Feature Writer Dec 5, 2014

Zoetis, Apple, Yahoo!, and a couple of other overhyped stocks are ripe for pullbacks. Don't wait for the meltdown to start before heading for the exit.

11 Biotechnology Stocks to Buy Now

By Portfolio Grader Nov 12, 2014

This week, 11 biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").

9 Biotechnology Stocks to Buy Now

By Portfolio Grader Aug 27, 2014

This week, nine biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").

8 Biotechnology Stocks to Buy Now

By Portfolio Grader Aug 6, 2014

The grades of eight biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").

25 Small-Cap Stocks to Buy

By Jeff Reeves Jul 23, 2014

This list of 25 small-cap stocks to buy includes some tech stocks and consumer plays that could add 25% in the next year.

Agios Pharmaceuticals GAAP EPS of -$4.23 beats by $2.06, revenue of $14.24M beats by $0.35M (NASDAQ:AGIO)

From Seeking Alpha Feb 23, 2023

Agios Pharmaceuticals press release (AGIO): FY GAAP EPS of -$4.23 beats by $2.06.Revenue of $14.24M beats by $0.35M.$1.1 Billion of Cash, Cash Equivalents and Marketable Securities...

3 Under-the-Radar Biotech Stocks to Buy in 2022

From The Motley Fool Dec 24, 2022

The attraction of all three biotech stocks is their potential.

Agios rare blood disorder drug Pyrukynd sustains benefits in long term data

From Seeking Alpha Dec 12, 2022

Agios Pharmaceuticals (AGIO) said long term data suggested that Pyrukynd led to improvements in hemoglobin, iron overload, transfusion burden and patient-reported outcomes, regardless...

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Agios Pharma (AGIO)

From TipRanks Dec 1, 2022

Analysts fell to the sidelines weighing in on Gilead Sciences (GILD – Research Report) and Agios Pharma (AGIO – Research Report) with neutral ratin...

Agios Pharmaceuticals upgraded to neutral at Goldman Sachs (NASDAQ:AGIO)

From Seeking Alpha Nov 17, 2022

Goldman Sachs has upgraded Agios Pharmaceuticals (AGIO) to neutral from sell on upcoming data releases on pyruvate kinase (PKR) activator Pyrukynd (mitapivat).

SVB Securities Reaffirms Their Buy Rating on Agios Pharma (AGIO)

From TipRanks Nov 7, 2022

In a report released on November 3, Andrew Berens from SVB Securities reiterated a Buy rating on Agios Pharma (AGIO – Research Report), with a price target of...